NASDAQ:GLYCGlycoMimetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GlycoMimetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.89 +0.01 (+0.26 %) (As of 08/7/2020 02:03 PM ET) Add Compare Share Today's Range$3.82Now: $3.89▼$3.9550-Day Range$2.98MA: $3.90▼$5.0052-Week Range$1.82Now: $3.89▼$6.72Volume14,793 shsAverage Volume643,735 shsMarket Capitalization$185.63 millionP/E RatioN/ADividend YieldN/ABeta2.52 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.67, GlycoMimetics has a potential upside of 152.4% from its current price of $3.83.Amount of Analyst CoverageGlycoMimetics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesGlycoMimetics has received 300 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGlycoMimetics has received 262 “underperform” votes. (Add your “underperform” vote.)Community SentimentGlycoMimetics has received 53.38% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote “Outperform” if you believe GLYC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 26.80% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions91.04% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to decrease in the coming year, from ($1.17) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLYC Previous Symbol CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone240-243-1201Debt Debt-to-Equity Ratio0.02 Current Ratio15.81 Quick Ratio14.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book1.28Profitability EPS (Most Recent Fiscal Year)($1.34) Net Income$-57,890,000.00 Net MarginsN/A Return on Equity-32.31% Return on Assets-29.73%Miscellaneous Employees50 Outstanding Shares47,720,000Market Cap$185.63 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $3.89 +0.01 (+0.26 %) (As of 08/7/2020 02:03 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GLYC News and Ratings via Email Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions How has GlycoMimetics' stock been impacted by COVID-19 (Coronavirus)? GlycoMimetics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GLYC shares have increased by 32.3% and is now trading at $3.89. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of GlycoMimetics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GlycoMimetics. When is GlycoMimetics' next earnings date? GlycoMimetics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for GlycoMimetics. How were GlycoMimetics' earnings last quarter? GlycoMimetics Inc (NASDAQ:GLYC) released its quarterly earnings results on Friday, July, 31st. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. View GlycoMimetics' earnings history. What price target have analysts set for GLYC? 4 analysts have issued 12-month price objectives for GlycoMimetics' stock. Their forecasts range from $5.00 to $15.00. On average, they anticipate GlycoMimetics' stock price to reach $9.67 in the next twelve months. This suggests a possible upside of 148.5% from the stock's current price. View analysts' price targets for GlycoMimetics. Has GlycoMimetics been receiving favorable news coverage? Press coverage about GLYC stock has been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GlycoMimetics earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about GlycoMimetics. Are investors shorting GlycoMimetics? GlycoMimetics saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 2,480,000 shares, a drop of 11.1% from the July 15th total of 2,790,000 shares. Based on an average trading volume of 760,900 shares, the short-interest ratio is currently 3.3 days. Approximately 7.4% of the shares of the stock are short sold. View GlycoMimetics' Current Options Chain. Who are some of GlycoMimetics' key competitors? Some companies that are related to GlycoMimetics include Vectura Group (VEGPF), ORIC Pharmaceuticals (ORIC), Dynavax Technologies (DVAX), Assembly Biosciences (ASMB), Nkarta (NKTX), Legend Biotech (AMTI), ZIOPHARM Oncology (ZIOP), Akouos (AKUS), Passage Bio (KROS), ImmunoGen (IMGN), Tricida (TCDA), Frequency Therapeutics (FREQ), Trillium Therapeutics (TRIL), Eagle Pharmaceuticals (EGRX) and Vanda Pharmaceuticals (VNDA). View all competitors. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), Vanda Pharmaceuticals (VNDA), Exelixis (EXEL), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO) and Fate Therapeutics (FATE). Who are GlycoMimetics' key executives? GlycoMimetics' management team includes the following people: Ms. Rachel K. King, Pres, CEO & Director (Age 60)Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)Mr. Henry Flanner, VP of Technical Operations What is GlycoMimetics' stock symbol? GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC." Who are GlycoMimetics' major shareholders? GlycoMimetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.12%), First Quadrant L P CA (0.06%), Leap Investments LP (0.06%), Russell Investments Group Ltd. (0.05%), Diversified Trust Co (0.04%) and ProShare Advisors LLC (0.03%). Company insiders that own GlycoMimetics stock include Bvf Partners L P/Il, Daniel M Junius and John L Magnani. View institutional ownership trends for GlycoMimetics. Which institutional investors are selling GlycoMimetics stock? GLYC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View insider buying and selling activity for GlycoMimetics. Which institutional investors are buying GlycoMimetics stock? GLYC stock was purchased by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Russell Investments Group Ltd., Diversified Trust Co, ProShare Advisors LLC, and Leap Investments LP. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il, and Daniel M Junius. View insider buying and selling activity for GlycoMimetics. How do I buy shares of GlycoMimetics? Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GlycoMimetics' stock price today? One share of GLYC stock can currently be purchased for approximately $3.89. How big of a company is GlycoMimetics? GlycoMimetics has a market capitalization of $185.63 million. The biotechnology company earns $-57,890,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe. What is GlycoMimetics' official website? The official website for GlycoMimetics is www.glycomimetics.com. How can I contact GlycoMimetics? GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
